COLONY GROUP LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.

Quarter-by-quarter ownership
COLONY GROUP LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,071
+5.9%
80,387
+0.0%
0.05%
+12.2%
Q2 2023$2,899
-5.7%
80,382
-0.1%
0.04%
-10.9%
Q1 2023$3,074
-33.8%
80,486
-1.3%
0.05%
-29.2%
Q4 2022$4,642
-99.9%
81,578
+1.9%
0.06%
+16.1%
Q3 2022$3,164,000
-11.6%
80,023
-1.6%
0.06%
-9.7%
Q2 2022$3,578,000
+11.0%
81,315
+0.6%
0.06%
+29.2%
Q1 2022$3,222,000
+0.2%
80,804
+1.1%
0.05%
-14.3%
Q4 2021$3,215,000
+6.6%
79,945
+7.8%
0.06%
-3.4%
Q3 2021$3,017,000
-9.5%
74,158
+1.0%
0.06%
-12.1%
Q2 2021$3,335,000
+8.8%
73,445
-0.1%
0.07%
+3.1%
Q1 2021$3,066,000
-10.4%
73,548
-8.2%
0.06%
-19.0%
Q4 2020$3,421,000
+60.4%
80,097
-1.3%
0.08%
+41.1%
Q3 2020$2,133,000
-34.5%
81,161
-33.2%
0.06%
-40.4%
Q2 2020$3,257,000
+49.1%
121,495
+0.1%
0.09%
+32.4%
Q1 2020$2,184,000
+73.7%
121,388
+71.2%
0.07%
+121.9%
Q4 2019$1,257,000
+15.3%
70,920
+0.9%
0.03%
-8.6%
Q3 2019$1,090,000
-10.0%
70,260
-0.3%
0.04%
-7.9%
Q2 2019$1,211,000
+8.4%
70,490
+1.6%
0.04%
-19.1%
Q1 2019$1,117,000
+85.9%
69,395
+69.0%
0.05%
+62.1%
Q4 2018$601,000
-54.3%
41,065
-43.3%
0.03%
-56.1%
Q3 2018$1,316,000
+7.4%
72,420
-0.3%
0.07%
+3.1%
Q2 2018$1,225,00072,6400.06%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders